scholarly journals Variation of the Absorbed Dose by the Weight of the Patient in CT Scanning

2021 ◽  
Vol 4 (2) ◽  
pp. 83-86
Author(s):  
İsmail Hakkı SARPÜN ◽  
Cengiz ÖZSOY ◽  
Vedat AYDIN ◽  
Timur KOCA
Keyword(s):  
Absorbed Dose ◽  
Ct Scanning

1522: Utility of Preoperative 3-D Reconstruction of Pelvic Vasculature using Multi-Detector Spiral CT Scanning in Treatment Planning for Robotic Prostatectomy

2005 ◽  
Vol 173 (4S) ◽  
pp. 412-412
Author(s):  
Ashutosh Tewari ◽  
Assaad El-Hakim ◽  
Peter N. Schlegel ◽  
Mani Menon ◽  
Deirdre M. Coll
Keyword(s):  
Treatment Planning ◽  
Ct Scanning ◽  
Spiral Ct ◽  
Robotic Prostatectomy

CT Scanning Interferes With Pacemakers, Other Devices

2008 ◽  
Vol 38 (16) ◽  
pp. 5
Author(s):  
ELIZABETH MECHCATIE
Keyword(s):  
Ct Scanning

Characterization of radioiodine therapy failures in Graves’ disease

2001 ◽  
Vol 40 (01) ◽  
pp. 1-6 ◽  
Author(s):  
M. Zimny ◽  
M. Schreckenberger ◽  
P. Reinartz ◽  
B. Nowak ◽  
E. Ostwald ◽  
...  
Keyword(s):  
Radioiodine Therapy ◽  
Thyroid Volume ◽  
Absorbed Dose ◽  
Stepwise Logistic Regression ◽  
Graves Disease ◽  
Significant Variable ◽  
Absorbed Energy ◽  
Volume Function ◽  
Energy Dose

Summary Aim of this study was a characterization of radioiodine therapy (RIT) failures in Graves’ disease without simultaneous Carbimazole. Method: 226 patients with a confirmed diagnosis of Graves’ disease received 686.8 ± 376.4 MBq of iodine-131 orally for thyroid ablation. Target dose was 250 Gy. All patients were followed up for 6 months. Therapy failures were compared with successes regarding possible influencing variables initial thyroid volume, thyroid function, immune activity (TRAb), 1-131 uptake, effective half-life, absorbed energy dose, age and gender. Results: 212 of 226 patients (93.8%) were treated successfully, 14 (6.2%) showed a hyperthyroidism relapse within 6 months which required a second radioiodine therapy. A success rate of 92.5% (62/67) could also be achieved with 67 patients who were hyperthyroid at the time of RIT. Compared to the therapy successes, the 14 failures achieved significantly lower absorbed doses (223.8 ±76.6 Gyvs. 285.2 ±82.1 Gy, ρ <0.005), but with no significant differences regarding age, thyroid volume, function or TRAb (all ρ >0.2). Of the 14 failures, η = 8 reached an absorbed dose <200 Gy and η = 1 a dose <250 Gy, although 5 of the failures reached an absorbed dose of >250 Gy. Stepwise logistic regression revealed only absorbed energy dose as a variable significantly influencing therapy success (p <0.005), but no influence of initial thyroid volume, function, TRAb value, age (all ρ >0.2) or gender (p = 0.13). Two-tailed Fisher’s exact test showed no significant influence of gender on success rates (failures/successes: male 1 /36, female 13/176, ρ = 0.48). Conclusions: Except for the absorbed energy dose, no other significant variable influencing the outcome of radioiodine therapy in Graves’ disease without simultaneous Carbimazole could be found. It should be noted, though, that 5 therapy failures (2.2%) reached an absorbed energy dose of >250 Gy.

Dosimetry with 188Re-labelled monoclonal anti-CD66 antibodies

2006 ◽  
Vol 45 (03) ◽  
pp. 134-138 ◽  
Author(s):  
T. Kull ◽  
N. M. Blumstein ◽  
D. Bunjes ◽  
B. Neumaier ◽  
A. K. Buck ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Bone Marrow ◽  
Gamma Camera ◽  
Absorbed Dose ◽  
Correlation Coefficients ◽  
Residence Times ◽  
Reliable Prediction ◽  
Red Bone Marrow ◽  
Antibody Preparation ◽  
Simplified Method

SummaryAim: For the therapeutic application of radiopharmaceuticals the activity is determined on an individual basis. Here we investigated the accuracy for a simplified assessment of the residence times for a 188Re-labelled anti-CD66 monoclonal antibody. Patients, methods: For 49 patients with high risk leukaemia (24 men, 25 women, age: 44 ± 12 years) the residence times were determined for the injected 188Re-labelled anti-CD66 antibodies (1.3 ± 0.4 GBq, 5–7 GBq/mg protein, >95% 188Re bound to the antibody) based on 5 measurements (1.5, 3, 20, 26, and 44 h p.i.) using planar conjugate view gamma camera images (complete method). In a simplified method the residence times were calculated based on a single measurement 3 h p.i. Results: The residence times for kidneys, liver, red bone marrow, spleen and remainder of body for the complete method were 0.4 ± 0.2 h, 1.9 ± 0.8 h, 7.8 ± 2.1 h, 0.6 ± 0.3 h and 8.6 ± 2.1 h, respectively. For all organs a linear correlation exists between the residence times of the complete method and the simplified method with the slopes (correlation coefficients R > 0.89) of 0.89, 0.99, 1.23, 1.13 and 1.09 for kidneys, liver, red bone marrow, spleen and remainder of body, respectively. Conclusion: The proposed approach allows reliable prediction of biokinetics of 188Re-labelled anti-CD66 monoclonal antibody biodistribution with a single study. Efficient pretherapeutic estimation of organ absorbed dose may be possible, provided that a more stable anti-CD66 antibody preparation is available.

Superselective Radioembolization of Hepatocellular Carcinoma: 5-Year Results of a Prospective Study

1994 ◽  
Vol 33 (05) ◽  
pp. 206-214 ◽  
Author(s):  
J. Triller ◽  
H. U. Baer ◽  
Livia Geiger ◽  
H. F. Beer ◽  
C. Becker ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Survival Rates ◽  
Absorbed Dose ◽  
Pulmonary Complications ◽  
Pulmonary Shunt ◽  
Recurrent Tumour ◽  
Activity Distribution ◽  
A Prospective Study ◽  
Overall Survival Rates

SummaryTwenty patients with unresectable hepatocellular carcinoma (HCC) were followed up to 5 years after transarterial radiotherapy with 90Y-resin particles. Diagnostic radioembolizations of 99mTc-macroaggregates facilitated scintigraphic assessment of activity distribution, dose evaluation and final procedural verification. The overall survival rates were 56, 38 and 14% (after 1, 2 and 3 years, resp.). Patients with unifocal HCC and a single feeding artery (n = 7) even presented 83, 67 and 40% (2 alive after 2.75 and 4 years). With multiple arteries (n = 7), the longest survival was 26 months. Patients with multifocal HCC survived up to 33 months after selective radioembolization. Quality of life was improved in all. Survival was positively correlated with absorbed dose but residual/recurrent tumour occurred even after ≥300 Gy. Post-treatment symptoms were minimal (35 applications), pulmonary shunt rates were correctly predicted and pulmonary complications avoided.

Morphology and Affinities of Ampelocissites Seeds (Vitaceae: Ampelopsis clade) from the Paleogene of Texas, USA

2020 ◽  
Vol 45 (3) ◽  
pp. 478-482
Author(s):  
Steven R. Manchester
Keyword(s):  
Computed Tomography ◽  
Cross Sections ◽  
Seed Coat ◽  
Ct Scanning ◽  
Seed Morphology ◽  
Early Eocene ◽  
Micro Computed Tomography ◽  
X Ray ◽  
Fossil Seeds ◽  
Fossil Genus

Abstract—The type material on which the fossil genus name Ampelocissites was established in 1929 has been reexamined with the aid of X-ray micro-computed tomography (μ-CT) scanning and compared with seeds of extant taxa to assess the relationships of these fossils within the grape family, Vitaceae. The specimens were collected from a sandstone of late Paleocene or early Eocene age. Although originally inferred by Berry to be intermediate in morphology between Ampelocissus and Vitis, the newly revealed details of seed morphology indicate that these seeds represent instead the Ampelopsis clade. Digital cross sections show that the seed coat maintains its thickness over the external surfaces, but diminishes quickly in the ventral infolds. This feature, along with the elliptical chalaza and lack of an apical groove, indicate that Ampelocissites lytlensis Berry probably represents Ampelopsis or Nekemias (rather than Ampelocissus or Vitis) and that the generic name Ampelocissites may be useful for fossil seeds with morphology consistent with the Ampelopsis clade that lack sufficient characters to specify placement within one of these extant genera.

Sign in / Sign up

Export Citation Format

Share Document